KR860700264A - 림포킨 생산 및 정제 - Google Patents

림포킨 생산 및 정제

Info

Publication number
KR860700264A
KR860700264A KR1019860700138A KR860700138A KR860700264A KR 860700264 A KR860700264 A KR 860700264A KR 1019860700138 A KR1019860700138 A KR 1019860700138A KR 860700138 A KR860700138 A KR 860700138A KR 860700264 A KR860700264 A KR 860700264A
Authority
KR
South Korea
Prior art keywords
csf
protein
cdna
activity
amino acid
Prior art date
Application number
KR1019860700138A
Other languages
English (en)
Other versions
KR910001809B1 (ko
Inventor
씨. 클라크 스티븐
제이. 카우프만 란달
웡 고르돈 지
에이. 왕 엘리자베스
Original Assignee
예안 크라메르,한스 루돌프 하우스
산도즈 아크티엔 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27417446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR860700264(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 예안 크라메르,한스 루돌프 하우스, 산도즈 아크티엔 게젤샤프트 filed Critical 예안 크라메르,한스 루돌프 하우스
Publication of KR860700264A publication Critical patent/KR860700264A/ko
Application granted granted Critical
Publication of KR910001809B1 publication Critical patent/KR910001809B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Debugging And Monitoring (AREA)
  • Fats And Perfumes (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Detergent Compositions (AREA)

Abstract

내용 없음

Description

림포킨 생산 및 정제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본 발명에 의한 CPS단백질을 암호하는 DNA서열을 나타낸다. DNA서열은 인체 CSF의 하나의 변이(CSF-Thr)에 대한 코드를 전부 나타낸다. 다른 대립 유전자는 100으로 표시된 위치에서 Thr이 Ile로 대치된다(CSF-Ile)는 것을 제외하고는 동일한 생산물을 암호한다. 인체서열에 대해 상술한 변화는 긴팔원숭이(gibbon) CSF (CSF-G)를 암호하는 DNA서열에서와는 다르다. 연역한 아미노산 서열이 또한 표시되어 있다.

Claims (18)

  1. 재조합 CSF단백질.
  2. 골수 분석에서 1×107단위/㎎의 특이활성을 갖는 CSF단백질.
  3. 제2항에 있어서, 재조합 CSF단백질.
  4. 제1항에 있어서, 인체 과립구-대식기 CSF단백질.
  5. 제1항에 있어서, 제1도에서 CSF-Thr에 대하여 또는 CSF-ile에 대하여 또는 CSF-G에 대하여 나타낸 아미노산 서열을 가지는 CSF단백질.
  6. 제1항에 있어서, Ala, Pro…로 시작되는 제1도에 나타낸바의 아미노산 서열 또는 메티오닌 잔기가 선행된 Ala.Pro로 시작하는 아미노산 서열을 함유하는 CSF단백질.
  7. 제1항에 있어서, 천연 CSF의 생물학적 활성에 거의 영향을 미치지 않고서 하나이상의 아미노산이부가, 치환 또는 제거되는 것을 제외하고는 그 아미노산 서열에 있어서 CSF단백질이 천연 발생한 CSF에 해당하는 CSF단백질.
  8. 제1항에 있어서, 메티오닌 잔기가 선행되는 것을 제외하고는, 그 단백질이 천연 CSF의 아미노산 서열을 가지는 CSF단백질.
  9. CSF단백질을 암호하는 유전자가 삽입된 벡터로써 형질전환된 진핵 또는 원핵 숙주 세포로부터 표현된 CSF단백질을 분리하는 것을 특징으로 하는 CSF단백질의 생산방법.
  10. 제9항에 있어서, 그 표현이 E.coli CHO 또는 효모로부터 유도되는 것을 특징으로 하는 방법.
  11. CSF를 생산하는 세포로부터 RNA를 제조하고; 그 RNA로부터 폴리아데닐화 mRNA를 제조하여 그 mRNA로부터 단일쇄 cDNA를 제조한 후 일본쇄 cDNA를 이본쇄 cDNA로 전환시키고; 이본쇄 cDNA를 형질전환 벡터에 삽입, 그 벡터로써 박테리아를 형질전환시켜 콜로니를 형성시키고; 200 내지 500콜로니들의 각각의 푸울을 선발하여 각 푸울로부터 플라스미드 DNA를 분리; 그 플라스미드 DNA를 CSF단백질을 포현하는 적합한 숙주 세포에 트랜스펙숀하며; 트랜스펙숀된(이입)셀을 배양하여 CSF 활성에 대해 그 상청액을 분석하고; CSF 양성 푸울을 선발, 푸울제조에 사용된 콜로니를 스크리닝하여 CSF 활성을 갖는 콜로니를 동정하는 것을 특징으로 하는, CSF/cDNA 함유의 형질전환 벡터의 제조 및 분리방법.
  12. 암모늄 설페이트로써 단백질을 80% 포화 침전시켜서 VCSF단백질이 함유된 펠릿을 형성시키고; 그 펠릿을 약 6 내지 8의 pH에서 완충 제용액에 재현탁시키고; CSF 함유의 완충 용액을 크로마토그래프 컬럼에 적용시키고, 염화나트륨 함유의 완충 용액으로 CSF 활성을 용출시켜 CSF 활성을 갖는 분획을 수거하며; 그 활성 분획을 혼주하고, 그 혼주된 분획들을 C4역상 컬럼에 적용시킨 후 0 내지 90% 아세토니트릴 그래디언트로 CSF 활성을 용출시켜 CSF 활성이 함유된 분획을 수거하는 것을 특징으로 하는 수용성, 배지에 현탁된 단백질 혼합물로부터 CSF단백질을 정제하는 방법.
  13. 제1항의 CSF를 암호하는 cDNA 또는 표현 벡터.
  14. 제1항의 CSF를 함유하는 약학 조성물 또는 치료 목적의 제1항의 CSF.
  15. 치료가 필요한 동물에 제1항의 CSF를 투여하는 것을 특징으로 하는 동물의 감염 또는 과립구 감소증의 치료 또는 호중구의 활성화 방법. 또는 그 방법을 위한 약학 조성물 제조에 사용되는 제1항의 CSF의 용도.
  16. 제12항의 방법으로 제조된 CSF를 암호하는 약학 조성물.
  17. 치료가 필요한 동물에 제12항의 CSF를 투여하여 포유동물의 감염 또는 과립구 감소증의 치료 또는 호중구 활성화 방법 또는 그 방법을 위한 약학 조성물 제조에 사용되는 제12항의 CSF의 용도.
  18. ATCC 제39754호로 ATCC에 기탁된 E.coli MC1061 또는 그에 기탁된 플라스미드 p91023 (B)-CSF의 127 아미노산 CSF 암호 뉴클레오티드 서열을 표현함으로써 얻을 수 있는 CSF단백질.
    ※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860700138A 1984-07-06 1985-07-04 Csf 단백질 생산방법 및 정제방법 KR910001809B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US62834284A 1984-07-06 1984-07-06
US628342 1984-07-06
US65244784A 1984-09-19 1984-09-19
US65274284A 1984-09-19 1984-09-19
US652742 1984-09-19
US652447 1984-09-19
PCT/EP1985/000326 WO1986000639A1 (en) 1984-07-06 1985-07-04 Lymphokine production and purification

Publications (2)

Publication Number Publication Date
KR860700264A true KR860700264A (ko) 1986-08-01
KR910001809B1 KR910001809B1 (ko) 1991-03-26

Family

ID=27417446

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860700138A KR910001809B1 (ko) 1984-07-06 1985-07-04 Csf 단백질 생산방법 및 정제방법

Country Status (28)

Country Link
EP (2) EP0188479B1 (ko)
JP (4) JP2540509B2 (ko)
KR (1) KR910001809B1 (ko)
AT (2) ATE172494T1 (ko)
AU (3) AU599572B2 (ko)
CA (2) CA1341618C (ko)
CY (1) CY1629A (ko)
DE (3) DE3584089D1 (ko)
DK (2) DK168709B1 (ko)
ES (1) ES8701226A1 (ko)
FI (1) FI108796B (ko)
GR (1) GR851643B (ko)
HK (2) HK111594A (ko)
HU (1) HU208711B (ko)
IE (2) IE930961L (ko)
IL (2) IL75725A (ko)
LU (1) LU88337I2 (ko)
MY (1) MY102902A (ko)
NL (1) NL930089I2 (ko)
NO (4) NO179455C (ko)
NZ (2) NZ212645A (ko)
PL (1) PL153139B1 (ko)
PT (1) PT80776B (ko)
SA (1) SA94150015A (ko)
SG (1) SG108991G (ko)
SK (1) SK505985A3 (ko)
UA (1) UA39161C2 (ko)
WO (1) WO1986000639A1 (ko)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
ZA856108B (en) * 1984-10-29 1986-10-29 Immunex Corp Cloning of human granulocyte-macrophage colony simulating factor gene
JP3038348B2 (ja) * 1984-11-20 2000-05-08 シェーリング コーポレイション ヒト顆粒状、マクロファージおよび好酸球の細胞増殖因子活性を示すポリペプチドをコードするｃＤＮＡクローン
EP0211899B1 (en) * 1985-02-05 1992-09-23 Cetus Oncology Corporation Purification of native colony stimulating factor-1
DE3681551D1 (de) * 1985-09-30 1991-10-24 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
JPS63502795A (ja) * 1985-10-03 1988-10-20 バイオジェン インコーポレイテッド 顆粒球‐マクロファージコロニー刺激因子‐様ポリペプチド、ｄｎａ配列、組換えｄｎａ分子並びに微生物細胞中でヒト顆粒球−マクロファ−ジコロニ−刺激因子−様ポリペプチドを高収量で生産する方法
CA1295567C (en) * 1988-07-25 1992-02-11 Lawrence T. Malek Expression system for the secretion of bioactive human granulocyte, macrophage-colony stimulating factor (gm-csf) and other heterologous proteins from streptomyces
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
US5298603A (en) * 1985-12-21 1994-03-29 Hoechst Aktiengesellschaft GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
GR871029B (en) 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
US5162111A (en) * 1986-07-30 1992-11-10 Grabstein Kenneth H Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
EP0256843A1 (en) * 1986-08-11 1988-02-24 Cetus Corporation Expression of g-csf and muteins thereof and their use
GB8624899D0 (en) * 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
EP0276846A3 (en) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
JP2521094B2 (ja) * 1987-04-28 1996-07-31 アムジェン、インコーポレーテッド ヒト顆粒球マクロファ―ジコロニ―刺激因子をコ―ドする合成ｄｎａ、そのｄｎａを含むプラスミド、およびそのｄｎａで形質転換された大腸菌
DE3853590T2 (de) * 1987-06-25 1996-01-04 Immunex Corp Rinder granulocyt-makrophagenkolonie stimulierender faktor.
US5391706A (en) * 1987-07-16 1995-02-21 Schering Plough Corporation Purification of GM-CSF
ATE79884T1 (de) * 1987-07-16 1992-09-15 Schering Corp Reinigung von gm-csf.
AU626530B2 (en) * 1987-07-17 1992-08-06 Schering Biotech Corporation Human granulocyte-macrophage colony stimulating factor and muteins thereof
IE63514B1 (en) * 1987-07-17 1995-05-03 Schering Biotech Corp Expression vectors for the production of human granulocyte-macrophage colony stimulation factor in a mammalian cell host
AU2251488A (en) * 1987-07-24 1989-03-01 Cetus Corporation Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system
AU3834589A (en) * 1988-05-31 1990-01-05 Schering Biotech Corporation Method of treating myeloid leukemias
AU618283B2 (en) * 1988-10-10 1991-12-19 Instituto Nazionale Per Lo Studio E La Cura Dei Tumori The use of GM-CSF in the treatment of a patient requiring high-dose chemo- or radiotherapy for cancer
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
JPH0322973A (ja) * 1989-01-19 1991-01-31 Wan Shen-Yuan ヒトヘパトーム細胞系によるコロニー形成促進因子（ＣＳＦｓ）の構成性産生
KR920701246A (ko) * 1989-07-14 1992-08-11 스타이나 브이. 칸스타드 카르복실 말단으로부터 유도된 gm-csf의 길항제
DE69326829D1 (de) 1992-02-28 1999-11-25 Univ Texas Verwendung einer therapeutischen ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON VERBRENNUNGEN
US6004807A (en) * 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5772992A (en) * 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US6153183A (en) * 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US6403076B1 (en) 1992-11-24 2002-06-11 S. Christopher Bauer Compositions for increasing hematopoiesis with interleukin-3 mutants
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US6413509B1 (en) 1992-11-24 2002-07-02 S. Christopher Bauer Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
US7091319B1 (en) 1992-11-24 2006-08-15 Bauer S Christopher IL-3 variant hematopoiesis fusion protein
US6361977B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Methods of using multivariant IL-3 hematopoiesis fusion protein
US6361976B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
EP2272959A1 (en) 1993-05-12 2011-01-12 Genetics Institute, LLC BMP-11 compositions
DE69331268T2 (de) * 1993-06-30 2002-06-13 Lucky Ltd Modifizierte-Granulocyte-Makrophage-Kolonie-stimulierender-Faktor-Gen und seine Expression in Hefe
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
US5599536A (en) * 1993-12-13 1997-02-04 Sandoz Ltd. Method for suppressing the acute phase response in a patient receiving IL-6 therapy
US5578301A (en) * 1993-12-14 1996-11-26 Sandoz Ltd. Method for using GM-CSF to reduce the acute phase response in a patient being administered IL-6 therapy
US6165748A (en) 1997-07-11 2000-12-26 Genetics Institute, Inc. Frazzled nucleotide sequences and expression products
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
WO2000047195A1 (en) * 1999-02-12 2000-08-17 Washington University Stimulating neutrophil function to treat inflammatory bowel disease
EP1276899A2 (en) * 1999-12-10 2003-01-22 Whitehead Institute For Biomedical Research Ibd-related polymorphisms
US6869762B1 (en) 1999-12-10 2005-03-22 Whitehead Institute For Biomedical Research Crohn's disease-related polymorphisms
US6689599B1 (en) 2000-10-20 2004-02-10 Genetics Institute, Llc Aggrecanase molecules
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
WO2003012038A2 (en) 2001-07-27 2003-02-13 Wyeth Aggrecanase molecules
AU2003207795B2 (en) 2002-01-31 2009-01-08 Wyeth Aggrecanase molecules
US7150983B2 (en) 2002-02-05 2006-12-19 Wyeth Truncated aggrecanase molecules
EP1525307A2 (en) 2002-07-29 2005-04-27 Wyeth Modified adamts4 molecules and method of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428632A (en) * 1979-08-10 1984-01-31 Thomas & Betts Corporation Coaxial cable transition connector
JPS6030654B2 (ja) * 1980-12-31 1985-07-17 株式会社林原生物化学研究所 ヒトコロニ−刺激因子の製造方法
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
JPH0751511B2 (ja) * 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
ZA856108B (en) * 1984-10-29 1986-10-29 Immunex Corp Cloning of human granulocyte-macrophage colony simulating factor gene

Also Published As

Publication number Publication date
GR851643B (ko) 1985-11-26
NO1996016I1 (no) 1996-12-18
MY102902A (en) 1993-03-31
UA39161C2 (uk) 2001-06-15
JP2594768B2 (ja) 1997-03-26
FI108796B (fi) 2002-03-28
JP2594743B2 (ja) 1997-03-26
JPH07163351A (ja) 1995-06-27
DK102886D0 (da) 1986-03-06
JP2540509B2 (ja) 1996-10-02
EP0337359A2 (en) 1989-10-18
DK172679B1 (da) 1999-05-17
JPS61502682A (ja) 1986-11-20
NO961452D0 (no) 1996-04-12
CA1341618C (en) 2011-07-19
DK168709B1 (da) 1994-05-24
AU628069B2 (en) 1992-09-10
CA1340852C (en) 1999-12-14
NO943300L (no) 1986-03-13
AU599572B2 (en) 1990-07-26
NO314941B1 (no) 2003-06-16
SA94150015B1 (ar) 2004-09-04
AU4009089A (en) 1989-12-07
EP0337359B1 (en) 1998-10-21
PL153139B1 (en) 1991-03-29
EP0188479B1 (en) 1991-09-11
AU4545685A (en) 1986-02-10
DK102886A (da) 1986-03-06
FI860308A (fi) 1986-01-22
SG108991G (en) 1992-03-20
SK280265B6 (sk) 1999-10-08
JPH06199897A (ja) 1994-07-19
DE3588199T2 (de) 1999-04-08
HK1011709A1 (en) 1999-07-16
IE851695L (en) 1986-01-06
IL94754A0 (en) 1991-04-15
SA94150015A (ar) 2005-12-03
EP0188479A1 (en) 1986-07-30
HK111594A (en) 1994-10-21
ES544868A0 (es) 1986-11-16
NO860775L (no) 1986-03-13
DE3584089D1 (de) 1991-10-17
SK505985A3 (en) 1999-10-08
PL254400A1 (en) 1986-06-17
HU208711B (en) 1993-12-28
NO179455B (no) 1996-07-01
PT80776A (en) 1985-08-01
NZ212645A (en) 1990-02-26
CY1629A (en) 1992-07-10
JP2594744B2 (ja) 1997-03-26
DK59493A (da) 1993-05-21
NO961452L (no) 1996-04-12
NO179455C (no) 1996-10-09
JPH06319557A (ja) 1994-11-22
AU644359B2 (en) 1993-12-09
FI860308A0 (fi) 1986-01-22
PT80776B (pt) 1987-09-30
IE60819B1 (en) 1994-08-10
WO1986000639A1 (en) 1986-01-30
DK59493D0 (da) 1993-05-21
IE930961L (en) 1986-01-06
EP0337359A3 (en) 1990-02-07
ES8701226A1 (es) 1986-11-16
NO943300D0 (no) 1994-09-07
ATE172494T1 (de) 1998-11-15
DE3588199D1 (de) 1998-11-26
NO307348B1 (no) 2000-03-20
IL75725A0 (en) 1985-11-29
NL930089I1 (nl) 1993-10-01
DE188479T1 (de) 1987-05-21
HUT38675A (en) 1986-06-30
NZ228031A (en) 1991-12-23
AU5497690A (en) 1990-09-13
NL930089I2 (nl) 1994-07-01
KR910001809B1 (ko) 1991-03-26
ATE67244T1 (de) 1991-09-15
IL75725A (en) 1993-02-21
LU88337I2 (fr) 1994-05-04

Similar Documents

Publication Publication Date Title
KR860700264A (ko) 림포킨 생산 및 정제
KR927002375A (ko) 거핵구 형성 인자
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
EP0219781A2 (de) Biologisch aktive Derivate des Human-gamma-Interferons, ihre Herstellung und Arzneimittel, die solche Derivate enthalten
DE3722673A1 (de) Fuer plasminogenaktivator-inhibitor, typ 2 (pai-2) codierende dna
Rosenberg 4894440 Method of isolating megakaryocyte stimulatory factor
IE930589L (en) Anti-lymphotoxin antibody, its production and use

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050202

Year of fee payment: 15

EXPY Expiration of term